Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease

Eur Respir J. 2022 Aug 10;60(2):2200930. doi: 10.1183/13993003.00930-2022. Print 2022 Aug.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Humans
  • Kidney
  • Liver Diseases* / drug therapy
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents